Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer.

ABSTRACT:

Background & aims

Patient-derived tumor organoids (PDTOs) are a reliable model for preclinical and translational studies. Despite positive retrospective correlations with patient response, challenges such as culture success, cost, standardization, and time constraints hinder their clinical utility in precision medicine. Here, we optimize PDTO establishment using growth factor-reduced media (GF-) to mitigate these challenges and (1) identify somatic variant indicators that can improve the therapeutic index of existing FDA-approved drugs against hepatocellular carcinoma (HCC), (2) elucidate synthetic lethal candidates against undruggable HCC driver mutations, and (3) assess the feasibility of PDTOs in personalized therapy.

Methods

We successfully established a panel of 23 PDTO

SUBMITTER: Wong AM 

PROVIDER: S-EPMC12205652 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature